Skip to content

Prospective paired clinical study of dynamic changes in L 3 SMI during active nutrition and exercise intervention during chemotherapy with albumin-paclitaxel

Prospective paired clinical study of dynamic changes in L 3 SMI during active nutrition and exercise intervention during chemotherapy with albumin-paclitaxel

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095637
Enrollment
Unknown
Registered
2025-01-09
Start date
2025-01-09
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Active Nutrition and Exercise Intervention Group:Active nutrition and exercise intervention

Sponsors

Ordos Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 years with pathologically confirmed cancer proposed to receive chemotherapy with albumin-paclitaxel regimen, with or without other drugs 2. KPS score of 70; 3. Before chemotherapy, liver and kidney work, blood routine and electrocardiogram were not abnormal, blood test must meet white blood cells> 3.5109 / L, neutrophils> 1.5109 / L, platelets> 85,109 / L, the upper limit of alkaline phosphatase 2.5 times, serum alanine transferase (ALT) and aspartate aminotransferase (AST) 3 times of normal, 1.5 times bilirubin, and the upper limit of creatinine. No other liver, kidney, or hematological diseases; 4. Patients with no relevant contraindications to chemotherapy; 5. No interventions (e. g. surgery) to change body composition between CT scan and initiation of chemotherapy; 6. Those who can receive BIA and CT; 7. Patients with no contraindications for small-to medium-intensity exercise 8. gave informed consent and signed the consent form.

Exclusion criteria

Exclusion criteria: 1,Patients with albumin-paclitaxel allergy; 2. The bedridden state could not cooperate with the nutrition assessors when enrolled; 3. Patients with other serious wasting diseases; 4. History of long-term use of hormones; 5. Self-termination of anti-tumor treatment or no regular constitution analysis or side reaction follow-up; 6. Motor contraindications are present 7. Patients who received prophylactic long-acting leukocyte elevation drugs before chemotherapy.

Design outcomes

Primary

MeasureTime frame
Index of the third lumbar vertebra corresponding to skeletal muscle;

Secondary

MeasureTime frame
Body Mass Index;

Countries

CHINA

Contacts

Public ContactLIQUANFU

Ordos Central Hospital

1729259137@qq.com+86 477 836 3279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026